BC Innovations | Jun 28, 2018
Translation in Brief

Conformist nanobodies

A University of Zurich team in collaboration with Roche has figured out how to make fully synthetic nanobodies that can bind to membrane proteins in specific conformations -- simultaneously opening up new target space for...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Innovations | Oct 20, 2016
Translation in Brief

Viking’s heart bypass

Viking Therapeutics Inc. (NASDAQ:VKTX) has presented data showing its preclinical thyroid hormone receptor β agonist, VK0214 , cut down pathogenic accumulation of very long chain fatty acids (VLCFAs) in a mouse model of X-linked adrenoleukodystrophy (X-ALD)....
BC Extra | Mar 27, 2015
Financial News

Cerenis raises EUR 53.4M in Euronext IPO

Cardiovascular play Cerenis Therapeutics S.A. (Euronext:CEREN) raised EUR 53.4 million ($57.7 million) through the sale of 4.2 million shares at EUR 12.70 in an IPO on Euronext. The IPO price values Cerenis at EUR 225.9...
BC Week In Review | Sep 15, 2014
Clinical News

Cerenis HDL regulatory update

Cerenis said the European Commission granted Orphan Drug designation to CER-001 to treat apolipoprotein A-1 (APOA1) and ATP-binding cassette transporter 1 ( ABCA1 ) deficiencies. The company said inherited defects in the APOA1 or ABCA1 gene can...
BC Innovations | Aug 21, 2014
Targets & Mechanisms

Corneal perspectives

Two independent findings could increase the availability of tissue for corneal transplants. A University of California, San Diego -led team has created a new source of limbal stem cells-which are needed for clear vision-by expressing...
BioCentury | Apr 21, 2014
Emerging Company Profile

Minoryx: Mediating rare metabolism

Minoryx Therapeutics S.L. has two complementary strategies for developing therapies to treat inherited metabolic diseases involving enzyme deficiencies: identifying small molecule chaperones that can restore mutant enzyme function, and repurposing existing drugs to treat the...
BioCentury | Jul 30, 2012
Finance

Blue skies for bluebird

Blue skies for bluebird Deerfield Partners made a rare investment in a private company last week when the hedge fund participated in gene therapy company bluebird bio Inc. 's $60 million series D round. Deerfield...
BC Week In Review | Aug 2, 2010
Clinical News

LIM-0705: Phase Ib data

In a double-blind, placebo-controlled, Australian Phase Ib trial in 44 healthy volunteers, tacrolimus plus placebo produced significant perturbations in glucose metabolism and kidney function, while tacrolimus plus oral LIM-0705 attenuated the effects. Both doses of...
BC Week In Review | Mar 15, 2010
Clinical News

LIM-0705: Phase Ia data

In the multiple-ascending dose portion of a Phase Ia trial in 28 healthy volunteers, LIM-0705 significantly reduced the tissue distribution of tacrolimus compared to tacrolimus alone (p<0.001). There were no serious adverse events. Patients received...
Items per page:
1 - 10 of 33